Spherix Incorporated Report issue

For profit Phase 3
Founded: New York NY United States (1967)
Status: Left NME R&D (2018)

Organization Overview

First Clinical Trial
2007
NCT00955747
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Robert Lodder

Active Ingredients

Drugs in Phase 3 Trials (2)

sucralose (1 trial)

tagatose (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus, Type 2 (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2